Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

HOUSTON, Aug. 04, 2022 -- Salarius Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options, announces the... | August 4, 2022

Related Keywords

New York ,United States ,Oregon Health Sciences University ,Oregon ,Memorial Sloan Kettering Cancer Center ,Portland ,Fox Chase Cancer Center ,Pennsylvania ,Missouri ,Texas ,Philadelphia ,Cleveland ,Ohio ,Boston ,Massachusetts ,Columbus ,Virginia ,Washington University ,Santa Monica ,Dana Farber Cancer Institute ,Petersburg ,Sankt Peterburg ,Russia ,Houston ,Los Angeles ,David Arthur ,Lee Cranmer ,Larae Davis ,Kim Sutton Golodetz ,School Of Medicine ,Linkedin ,Salarius Pharmaceuticals ,University Of Washington Medical Center ,Md Anderson Cancer Center ,Sarcoma Program Director ,Nasdaq ,Division Of Hematology Medical Oncology ,Salarius Pharmaceuticals Inc ,Seattle Cancer Care Alliance ,Product Development Award ,Research Institute Of Texas ,Globenewswire Inc ,Fred Hutchinson Cancer Research Center ,National Pediatric Cancer Foundation ,Knight Cancer Institute Translational Oncology Program ,Drug Administration ,Moffitt Cancer Center ,Oregon Health Sciences ,Sarcoma Oncology Center ,Exchange Commission ,Professor University Of Washington ,Cancer Care Alliance ,Hutchinson Cancer Research Center ,Washington Medical Center ,Sciences University ,Sarcoma Medical Oncology ,Associate Professor University ,Associate Professor ,Medical Oncology ,Sarcoma Program ,Johns Hopkins All Children ,Cancer Center ,Farber Cancer Institute ,Nationwide Children ,Sloan Kettering Cancer Center ,York City ,Cancer Specialists ,Chase Cancer Center ,Cancer Prevention ,Research Institute ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Nc Stock Exchange ,News ,Information ,Press Release ,022 ,Salarius ,Iopharmaceutical ,Company ,Developing ,Therapies ,Or ,Patients ,Ith ,Dancer ,N ,Need ,F ,Few ,Treatment ,Nnounces Slrx Us79400x1072 ,